Advertisement
Advertisement
U.S. Markets open in 3 hrs 42 mins
Advertisement
Advertisement
Advertisement
Advertisement

23andMe Holding Co. (ME)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
2.8300+0.3100 (+12.30%)
At close: 04:00PM EDT
2.8400 +0.01 (+0.35%)
Pre-Market: 04:24AM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close2.5200
Open2.6000
Bid0.0000 x 3100
Ask0.0000 x 2900
Day's Range2.5700 - 2.9100
52 Week Range2.1500 - 13.6800
Volume3,518,377
Avg. Volume3,484,566
Market Cap1.306B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.2120
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.50
  • GlobeNewswire

    23andMe to Report FY2022 Fourth Quarter and Full Year Financial Results

    SUNNYVALE, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, announced today that it will report financial results for the fiscal year 2022 (FY2022) fourth quarter and full year after the market closes on Thursday, May 26, 2022. The Company will webcast a conference call at 4:30 p.m. Eastern Time to discuss the quarter’s financial results and report on business progress. The webcast can be accessed on the day

  • Simply Wall St.

    Investors one-year losses grow to 69% as the stock sheds US$72m this past week

    Investing in stocks comes with the risk that the share price will fall. And unfortunately for 23andMe Holding Co...

  • Motley Fool

    23andMe CEO Anne Wojcicki on Bringing Health Information Directly to People

    In this podcast, Motley Fool contributor Brian Orelli interviews Anne Wojcicki, the CEO of 23andMe (NASDAQ: ME), about her company and why it's looking to tell you much more than the names of your long-lost relatives. To catch full episodes of all The Motley Fool's free podcasts, check out our podcast center. Anne Wojcicki: [MUSIC] When I think one of our legacies, hopefully, will be, is that 23andme has really proven that complicated information can go direct to a consumer, it does not have to have a one-to-one interaction with the physician.

Advertisement
Advertisement